Randox Laboratories last week launched several multi-marker drugs-of-abuse testing arrays. The biochips enable the analysis of up to 10 drug classes from a single patient sample.
Two drugs-of-abuse arrays are available: DoA array I contains markers for amphetamine, methamphetamine, barbituates, benzodiazepine 1 & 2, cannabinoids, cocaine metabolite, methadone, opiates, and phencyclidine; DoA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, LSD, MDMA, methaqualone, oxycodone 1 & 2, and propoxyphene. Creatinine is also included on the arrays as a marker of adulteration when testing urine samples. Both arrays are validated for use with urine and whole blood.
The biochips are designed for use with Randox's line of Evidence instruments.
Ocimum Biosolutions said last week that the National Cancer Institute has awarded its Biotracker laboratory information management system bronze-level compatibility certification for the Cancer Biomedical Informatics Grid.
Bronze compatibility certification guarantees that Biotracker LIMS is compliant with caBIG guidelines in four areas: programmatic access to data; use of controlled vocabularies; use and accessibility of data elements and metadata; and availability of a diagrammatic representation of the information model used.
DNAVision has been awarded Illumina CSPro certification to offer Infinium genotyping in its Belgium-based lab. DNAVision will now be able to offer Illumina genotyping arrays to European and other customers.